ライフサイエンスコーパス: plaque-forming unit

1 fection with the unadapted virus (ID(50) = 5 plaque-forming units).

2 ty when inoculated i.v. in high doses (10(9) plaque-forming units).

3 requencies ranging from 10(-5) to 10(-9) per plaque-forming unit.

4 oratory RUB strains and as low a dose as one plaque-forming unit.

5 antifies the infected area and the number of plaque-forming units.

6 in cell cultures ranged from 10(1) to 10(3) plaque-forming units/0.5 mL of a 10% stool suspension.

7 units; 70% for animals that received 3 x 10 plaque forming units; 0% for controls; p < 0.01 for each

8 The labeled phage (10(9) plaque-forming units, 1-3.7 MBq) was administered either

9 Plaque-forming units (106 or 108) of an adenovirus conta

10 rs, one eye was injected once with 8 X 10(8) plaque-forming units (20 microl) of the viral vector, wh

11 NP) and matrix protein 1 (M1) at 1.5 x 10(8) plaque forming units (4.3 x 10(8) 50% tissue culture inf

12 ntrols (60% for animals that received 3 x 10 plaque forming units; 70% for animals that received 3 x

13 tion values, we injected intradermally 10(9) plaque-forming unit adenovirus with the following transg

14 Each mouse received 1 x 10(9) plaque forming units administered i.v. 48 hr before the

15 le intramuscular dose of rVSV-ZEBOV (2x10(7) plaque-forming units administered in the deltoid muscle)

16 ation with rVSV-ZEBOV (one dose of 2 x 10(7) plaque-forming units, administered intramuscularly in th

17 i.v. administration of CG8840 (3.33 x 10(9) plaque-forming units/animal on day 1) and docetaxel (20

18 ion of MV-CEA at a total dose of 1.8 x 10(6) plaque forming units as assessed by magnetic resonance i

19 ncubation, and in less than 20 h it detected plaque-forming units at rates higher than 90% at 100% sp

20 , gene transfer was performed with 1 x 10(9) plaque-forming units by intravenous tail injection, 48 h

21 es of either CCSV or test vaccine (2.5x10(5) plaque-forming units) by 15 puncture scarification in do

22 wing day, they received G207 (10(7) or 10(8) plaque-forming units) by controlled-rate infusion over a

23 (HCMV) at a multiplicity of infection of 0.1 plaque-forming unit/cell and remained > 95% viable even

24 of 100% at a multiplicity of infection of 25 plaque-forming units/cell and persistence of foreign gen

25 ion of breast cancer cells with AdWTp53 (100 plaque-forming units/cell) resulted in 100% loss of the

26 knockout (ko) mice were infected with 10(5) plaque-forming units CVB3.

27 ts received 3 oral doses of vaccine (4 x 105 plaque-forming units/dose) or placebo at ages approximat

28 injection of recombinant adenoviruses (10(9) plaque-forming units) encoding the ligand-binding ectodo

29 ted [ITT-I] population) or RSV RNA >=1 log10 plaque-forming unit equivalents (PFUe)/mL (specific inte

30 l load (adjusted mean, 250.7 vs. 757.7 log10 plaque-forming-unit equivalents [PFUe] x hours per milli

31 roup were 59.9, 73.7, 133.4, and 500.9 log10 plaque-forming-unit equivalents x hours per milliliter,

32 AT(-)) (low phenotypic reactivator) at 10(4) plaque-forming units/eye.

33 AT(-)) (low phenotypic reactivator) at 10(4) plaque-forming units/eye.

34 tein, 120 fg for nucleocapsid protein, and 7 plaque forming units for intact virus, all within <30 mi

35 Our data show 5-log reduction in plaque forming units from a single lamp (single- pass an

36 ins of HSV-1-sensitive A/J mice at 2 x 10(6) plaque forming units, G47Delta was as safe as G207.

37 An HBRV dose of > or =8 x 10(6) plaque-forming units has demonstrated 68.8%-76.6% effica

38 laque-forming units (low dose) and 4 x 10(8) plaque-forming units (high dose) of rPLTP.AdV into mice,

39 Human cytomegalovirus (5 x 10(3) plaque forming unit in 0.1 ml Hank's balanced salt solut

40 owing to an increased ratio of particles to plaque-forming units in infections with the former.

41 + mice and was associated with increased RSV plaque-forming units in lung homogenates.

42 48/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broad

43 In vivo, Ad-hACE2-eGFP infection (2x10(6) plaque-forming units intracerebroventricularly) produced

44 ice were infected with adenovirus (3 x 10(9) plaque-forming units, intravenously) containing either C

45 Neurotoxicity studies, as defined by plaque-forming units/LD(50), performed in HSV-1-sensitiv

46 pounds exhibiting clinically relevant (10(1) plaque forming units) limit of detection.

47 After intravenous infusion of 4 x 10(7) plaque-forming units (low dose) and 4 x 10(8) plaque-for

48 MBaMV replication reached 10(3)-10(5) plaque-forming units ml(-1) in human epithelial cell lin

49 (a surrogate virus for SARS-CoV-2) at ~10(8) plaque-forming units mL(-1), reflecting the upper limits

50 mits of detection equivalent to less than 50 plaque forming units/mL (PFU/mL) were determined with vi

51 tilation at one of two concentrations (~1010 plaque forming units/mL or ~1011 plaque forming units/mL

52 sensitive in vitro yet grew robustly (>10(7) plaque forming units/mL) at the permissive temperature.

53 of an adenoviral construct (10 muL; 8x10(9) plaque forming units/mL) encoding green fluorescent prot

54 ions (~1010 plaque forming units/mL or ~1011 plaque forming units/mL).

55 ng units/mL; after 3 weeks, </= 4 mL x 10(8) plaque-forming units/mL every 2 weeks).

56 12), a cocktail of four phages (2-3 x 10(9) plaque-forming units/ml of 2003, 2002, 3A, and K; n = 12

57 ere labeled by directly injecting 8 x 10(10) plaque-forming units/ml of adenoviral GFP in 20-100 micr

58 V assay sensitivity was determined to be 3.2 plaque-forming units/mL using a reference virus culture

59 administered intratumorally in week 1 (10(6) plaque-forming units/mL), then in week 4 and every 2 wee

60 l vector used at identical titer (1 x 10(10) plaque-forming units/ml).

61 n week 4 and every 2 weeks thereafter (10(8) plaque-forming units/mL).

62 MV-ERV grew to 10(6) plaque-forming units/mL, slightly lower than the parenta

63 ms and shed live virus as high as 4.13 x 103 plaque-forming units/mL.

64 egan in week 1 (first dose, </= 4 mL x 10(6) plaque-forming units/mL; after 3 weeks, </= 4 mL x 10(8)

65 , did not appreciably affect HSV-1 function (plaque-forming units, normalized to viral particles meas

66 were treated with a total dose of 8 x 10(7) plaque forming units of MV-CEA, administered i.v.

67 4 followed by intramuscular injection of 108 plaque forming units of MVA-CMDR at weeks 12 and 24.

68 Mice were then given 10(9) plaque-forming units of a control vector (Ad.LacZ) or Ad

69 A single i.v. administration of 2 x 10(9) plaque-forming units of Ad-hOC-E1 inhibited the growth o

70 Using 1x10(9) plaque-forming units of Ad-LacZ (multiplicity of infecti

71 Intralesional injection of 5 x 10(8) plaque-forming units of AdCIFN-beta (but not AdLacZ) era

72 a single intravenous injection of 3 x 10(9) plaque-forming units of AdmVLDLR.

73 tu with saline alone (control), or 9 x 10(9) plaque-forming units of AdV-FasL.

74 First, 1.0 x 10(9) plaque-forming units of AdvBcl-2 in phosphate-buffered s

75 delay in healing, with vehicle, 106, or 108 plaque-forming units of an adenovirus containing the pla

76 Ischemic excisional wounds treated with 108 plaque-forming units of an adenovirus containing the pla

77 mean +/- SD, p < 0.05) when treated with 106 plaque-forming units of an adenovirus containing the pla

78 ean +/- SD, p < 0.001) when treated with 108 plaque-forming units of an adenovirus containing the pla

79 nstillation of either 1 x 10(9) or 4 x 10(9) plaque-forming units of an adenovirus that expresses an

80 A dose of 2 x 10(9) plaque-forming units of apoE4-expressing adenovirus redu

81 HepG2 cells were infected with 2 x 10(5) plaque-forming units of AvRB15 for 5, 10, 15, and 24 h.

82 oculated seven cynomolgus macaques with 1000 plaque-forming units of BDBV, administering rVSVDeltaG/B

83 bjects were inoculated intranasally with 100 plaque-forming units of coxsackievirus A21.

84 ) were infected intraperitoneally with 10(6) plaque-forming units of CVB3.

85 surfactant-based system to deliver 4 x 10(9) plaque-forming units of E1a-/E3- recombinant adenovirus

86 45 vaccines were combined in a dose of 10(5) plaque-forming units of each per 0.5-mL dose and compare

87 esus macaques received a target dose of 1000 plaque-forming units of Ebola virus intramuscularly with

88 Dams were challenged with 1 x 10(4) plaque-forming units of GPCMV in the third trimester.

89 ere intracamerally infected with 2.5 x 10(4) plaque-forming units of infectious HSV-1.

90 DIVER can detect 1 x 10(5) liposomes and 100 plaque-forming units of lentivirus and can successfully

91 fter supraciliary injection with 9.0 x 10(2) plaque-forming units of MCMV, 7 of 10 NK-depleted mice d

92 amide, were infected subretinally with 5x102 plaque-forming units of MCMV.

93 DBA/1 LacJ mice were administered 3 x 10(8) plaque-forming units of mIL-12 i.p. in a nonreplicating

94 ow-femtomole range, as estimated by titering plaque-forming units of MS2.

95 (1:1) to receive a single dose of 2 x 10(8) plaque-forming units of MVA-BN-Filo or saline placebo.

96 after intradermal vaccination with 5 x 10(7) plaque-forming units of MVA85A.

97 ) scid mice, which received 0.5 or 5 x 10(6) plaque-forming units of R4009, either were coinoculated

98 Patients with mCRPC received 2x10(8) plaque-forming units of recombinant vaccinia PSA-Tricom

99 ults were inoculated intranasally with 10(6) plaque-forming units of rHMPV-SHs.

100 BALB/c mice were infected with 10(7) plaque-forming units of RSV, in the presence or absence

101 provider to subcutaneous injections of 10(8) plaque-forming units of TG4010 or placebo from the begin

102 Rabbit eyes were infected with 10(5) plaque-forming units of the Dryvax strain of vaccinia vi

103 ere inoculated subcutaneously with 3.0 log10 plaque-forming units of the Guanarito virus prototype st

104 rsity of Wisconsin solution containing 10(9) plaque-forming units of the recombinant adenovirus.

105 ulation of CMV ocular infection, 9.0 x 10(2) plaque-forming units of the Smith strain of murine CMV (

106 her 2.5 x 10(5), 2.5 x 10(6), or 2.5 x 10(7) plaque-forming units of vaccine.

107 All mice vaccinated with 1 x 10(7) plaque-forming units of wild-type E7-vaccinia showed pro

108 enged 3 weeks later intramuscularly with 600 plaque-forming units of Zaire EBOV.

109 intratracheally with a high dose (3 x 10(6) plaque forming units) of SARS-CoV-2.

110 sed by the reduction in viral genomes and/or plaque forming units on treatment.

111 The effect of rat CMV (RCMV) (5x105 plaque-forming units) on TVS (neointimal index, NI) and

112 y probed by evaluating infective virions (as plaque forming units) or genomic damage (via the quantit

113 enous (IV) injection of GLV-1h153 (1 x 10(7) plaque-forming units) or phosphate buffered saline was t

114 given two doses of 89-12 (containing 1x10(5) plaque-forming units) or placebo, and 213 were followed

115 V)CFTR.10 at doses of 3 x 10(6) to 2 x 10(9) plaque-forming units over 9 months by endobronchial spra

116 nd received primary vaccination with 2x10(7) plaque-forming unit per mL of VSVDeltaG-ZEBOV-GP.

117 ous inoculation with 0.5 ml of a 1.4 x 10(3) plaque-forming unit per ml suspension of the attenuated

118 I.v. injections of GLV-1h68 (1x10(7) plaque-forming unit per mouse) into nude mice with estab

119 ion with RAd35 beta-Gal at 30, 100, and 1000 plaque-forming units per cell (pfu/cell), expression of

120 SERCA virus titers >5 to 6 plaque-forming units per cell produced overcrowding of A

121 At higher input multiplicities (10 plaque-forming units per cell), ADsubUL82 grew nearly as

122 ricted at low input multiplicities (0.01-0.1 plaque-forming units per cell), producing a yield that i

123 At mois > 3 plaque-forming units per cell, virus replication and pro

124 CA virus titer were maintained within 1 to 4 plaque-forming units per cell.

125 tectable by flow cytometry at an MOI of > 30 plaque-forming units per cell.

126 omegalovirus promoter at approximately 10(8) plaque-forming units per cornea for 48 hours.

127 after corneal scarification with 1.5 x 10(6) plaque-forming units per eye with one of the following r

128 e treated with CMX001 had titers 3-5 log(10) plaque-forming units per gram of tissue lower than sampl

129 ee animals received 1 x 10(10) to 1 x 10(11) plaque-forming units per kilogram by intravenous injecti

130 target, at low concentration values of 3-45 plaque-forming units per milliliter (pfu mL(-1)) with de

131 toilets at an initial concentration of 10(7) plaque-forming units per milliliter (PFU mL(-1)), were n

132 ney cells and achieved levels of 10(6)-10(7) plaque-forming units per ml of cell supernatant 6 days a

133 dicated by: high titres of MARV (10(3)-10(5) plaque-forming units per mL); development of leucocytosi

134 tion of the dengue 2 and dengue 3 viruses in plaque forming unit (PFU mL(-)(1)), giving detection lim

135 ectrodes enable the detection of less than 1 plaque forming unit (pfu)/mL in a direct EIS assay.

136 arget FAdVs and the electric signal up to 10 Plaque forming unit (PFU)/mL with a limit of detection (

137 Challenge with 10,000 plaque forming units (PFU) of EBOV was uniformly lethal,

138 es the viral titers remain high (10(5)-10(8) plaque forming units (pfu) per gram of tissue) for the l

139 ure injections of > 20 nanoliters of a 10(8) plaque forming units (pfu) per ml solution of virus were

140 Ad5CMVcatalase, with up to 10 plaque forming units (pfu) per neuron, did not affect ce

141 for vaccination containing either 1 x 10(7) plaque forming units (PFU) VSV-SUDV or 1 x 10(7) PFU of

142 1 through 5 in four dose cohorts: 1 x 10(9) plaque forming units (pfu), 1 x 10(10) pfu, 3 x 10(10) p

143 st generation assay is 10(2) and 10(2)-10(8) plaque forming units (pfu), respectively.

144 at a multiplicity of infection (MOI) of 10.0 plaque forming units (pfu)/cell at 48 hours.

145 infect SK-ChA-1 and HeLa cells at 10 and 100 plaque forming units (pfu)/cell, followed by FACS analys

146 acyclovir-resistant strain) was measured by plaque-forming unit (PFU) inhibition.

147 LS) regression correlating NIRS spectra with plaque-forming unit (PFU) measurements.

148 phal retention of phages of up to ~4 x 10(7) plaque-forming unit (PFU) mm(-2) (~2550 PFU mm(-2) s(-1)

149 5% chlorine was sufficient to ensure <8 Phi6 plaque-forming unit (PFU)/cm(2) in all tests.

150 roporation into cells, producing 2.9 x 10(6) plaque-forming unit (PFU)/mL of virus.

151 d titer equivalents 8.01 x 106 to 2.45 x 100 plaque-forming unit (PFU)/mL.

152 lthy adults were inoculated with 5.0 log(10) plaque-forming units (PFU) (n = 30) or 3.0 log10 PFU (n

153 oV-2 aerosol emission rates are high (>1,000 Plaque-forming units (PFU) / min).

154 d aerosol and average air detection was 1.00 plaque-forming units (pfu) and 0.08 pfu/m(3), respective

155 ine at 3 million, 20 million and 100 million plaque-forming units (PFU) and homologous VSV-Ebola vacc

156 t time points after inoculation of 2 x 10(4) plaque-forming units (PFU) HSV-1 (KOS strain) or an equi

157 ial (vaccine to placebo ratio, 2:1) at 105.7 plaque-forming units (PFU) in 15 RSV-seropositive 12- to

158 ed trial (vaccine-placebo ratio, 2:1) at 106 plaque-forming units (PFU) in 15 RSV-seropositive childr

159 roduces 45% survivors at a dose of 3 x 10(4) plaque-forming units (pfu) in a 9-day-old mouse model of

160 ted Ebola virus disease when used at 2 x 107 plaque-forming units (PFU) in a trial in Guinea.

161 ived 1 subcutaneous dose of 10, 100, or 1000 plaque-forming units (PFU) in cohorts of 3.

162 g ZIKV in oral samples with sensitivity of 5 plaque-forming units (PFU) in less than 40 min.

163 IL-17 cDNA targeted to the liver (5 x 10(9) plaque-forming units (PFU) intravenous) resulted in a tr

164 human bilirubin-UGT1 (Ad-hBUGT1) (3 x 10(9) plaque-forming units (pfu) intravenously) in adult bilir

165 3) were injected with 1 x 10(6) to 5 x 10(8) plaque-forming units (pfu) of Ad-hSSTr2-TK.

166 by subcutaneous inoculation of either 10(3) plaque-forming units (PFU) of DENV-1 or 10(5) PFU of DEN

167 9 days after intranasal infection with 10(5) plaque-forming units (pfu) of Influenza A strain WSN/33.

168 dult mice following infection with 5 x 10(5) plaque-forming units (PFU) of LACV.

169 -24 months received 1 intranasal dose of 105 plaque-forming units (PFU) of LID/DeltaM2-2/1030s (n = 2

170 Rhesus macaques given 5 x 10(4) or 1 x 10(5) plaque-forming units (pfu) of Rift Valley fever (RVF) MP

171 M-N95 respirator were inoculated with 10(6) plaque-forming units (PFU) of SARS-CoV-2 and were UV irr

172 infected with 10(4), 10(5), 10(6), or 10(7) plaque-forming units (pfu) of the Dryvax strain of the v

173 l BALB/c mice were inoculated with 4 X 10(4) plaque-forming units (PFU) of the KOS strain of HSV-1 us

174 t doses (3 x 10(8), 1 x 10(8), and 3 x 10(7) plaque-forming units (pfu) of the recombinant adenoviral

175 ty results in volunteers receiving 3 x 10(5) plaque-forming units (pfu) of the recombinant vesicular

176 ccination with 10(8.1), 10(7.2), and 10(7.0) plaque-forming units (pfu) of vaccinia virus per millili

177 This strategy yielded >1 x 10(3) plaque-forming units (pfu) of virus per ml of supernatan

178 fter nude mice were injected i.p. with 10(7) plaque-forming units (pfu) of WT, TK-, VGF-, or vvDD-GFP

179 f vaccine ranging from 300,000 to 50 million plaque-forming units (PFU) or placebo.

180 3 strain Dearing (T3D) at 0, 0.1, 1, and 10 plaque-forming units (PFU) per cell for 48 h.

181 OOP where CBA/J mice infected with 1 x 10(6) plaque-forming units (PFU) reovirus 1/L develop follicul

182 ymic BALB/c mice was injected with 1 x 10(4) plaque-forming units (PFU) to 2 x 10(4) PFU of herpes si

183 eived ONYX-015 at a daily dose of 1 x 10(10) plaque-forming units (pfu) via intratumoral injection fo

184 ts received a single vaccine dose of 2x10(4) plaque-forming units (PFU), 2x10(5) PFU, 2x10(6) PFU, or

185 atment groups: ChimeriVax-WN02 3.7- x -10(5) plaque-forming units (PFU), 3.7 x 10(4) PFU, 3.7 x 10(3)

186 ore permissive SCID mice with 10(5) or 10(7) plaque-forming units (PFU), respectively.

187 ect VV in concentrations from 10(3) to 10(8) plaque-forming units (PFU), with a limit of detection of

188 were injected with doses of up to 1 x 10(11) plaque-forming units (pfu).

189 o be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu).

190 ngeal virus titers peaked at 10(5.0)-10(6.0) plaque-forming units (pfu)/g of tissue from days 2 throu

191 A first-dose MTD of 12 x 10(9) plaque-forming units (PFU)/m(2) was established for outp

192 mits of detection for EBOV and SUDV were 465 plaque-forming units (PFU)/mL (1010 copies/mL) and 324 P

193 rmissive cell lines produced less than 0.7-7 plaque-forming units (PFU)/mL and in susceptible mice le

194 tation (LoQ) of the sensor are 1.28 and 3.89 plaque-forming units (PFU)/mL for S protein and 1.45 and

195 eceiving infectious titers of > or = 4X10(9) plaque-forming units (pfu)/mL showed endothelial activat

196 ection of this RT-LAMP assay was 2.8 x 10(2) plaque-forming units (PFU)/test and 1 x 10(3) PFU/test w

197 in 96-well plates was approximately 2 x 106 plaque-forming units (pfu)/well.

198 s, as revealed by their LD50 values: PR8, 32 plaque-forming units (PFU); HA(Min), 1.7 x 10(3) PFU; NA

199 In the open-label cohort, 1.0 x 10(7) plaque-forming units (PFU; low dose), 1.0 x 10(8) PFU (m

200 eas were inoculated bilaterally with 2x10(6) plaque-forming-units (PFU) of adenovirus type 5 (Ad5) af

201 xpressing Cre recombinase (Ad-Cre; 2 x 10(7) plaque forming units [PFU]) and adeno-associated viral v

202 Murine cytomegalovirus (9 x 10(2) plaque forming units [pfu]) was injected into the suprac

203 7 A(H5N1) virus-using a liquid inoculum (106 plaque forming units [PFU]), aerosol inhalation (15-16 P

204 tion (one 0.5 mL dose containing 2.5 x 10(4) plaque-forming units [PFU] of TDV-1; 6.3 x 10(3) PFU of

205 After ocular challenge with 2 x 10(5) plaque-forming units [pfu] per eye of HSV-1 strain McKra

206 needle with undiluted vaccine (dose, 10(7.8) plaque-forming units [pfu] per milliliter), a 1:10 dilut

207 n of HSV-1 strain McKrae (25 microL of 10(5) plaque-forming units [PFU]) in the scarified rabbit corn

208 Administration of a high dose (4 x 10(9) plaque-forming units [pfu]) of Av1ALAPH81 to mice result

209 istency lots of rVSVDeltaG-ZEBOV-GP (2 x 107 plaque-forming units [pfu]), high-dose 1 x 108 pfu, or p

210 received RSV/DeltaNS2/Delta1313/I1314L (106 plaque-forming units [PFU]), RSV/276 (105 PFU), or place

211 ose levels of Adp53 (1 x 10(6) to 1 x 10(11) plaque-forming units [PFU]).

212 ein (rVSV G-ZEBOV-GP; 3 x 10(5) to 1 x 10(8) plaque-forming units [pfu]).

213 (rVSVDeltaG-ZEBOV-GP; 3 x 10(5) to 1 x 10(8) plaque-forming units [pfu]).

214 in these models at low doses of EBOV (</=100 plaque-forming units [PFU]).

215 e doses of the rVSV-ZEBOV vaccine (3 million plaque-forming units [PFU], 20 million PFU, or 100 milli

216 1 of 3 lots of rVSVDeltaG- ZEBOV-GP (2 x 107 plaque-forming units [pfu], n = 797; combined-lots group

217 inally in adult pigmented rabbits (5 x 10(4) plaque-forming units [pfu]/eye).

218 ntrations associated with HFNO (2.66 x 10(4) plaque-forming units [PFU]/L of air sampled), nasal pron

219 ildren (mean peak titer, 10(4.3) vs. 10(2.5) plaque-forming units [pfu]/mL), indicating that the 1030

220 re inoculated intramuscularly with 6 x 10(3) plaque forming units (PFUs) of MP-12 vaccine.

221 of detection (LOD) for each test using viral plaque-forming units (PFUs) and viral RNA copy numbers o

222 solvents to yield on average 23 mL of 10(11) plaque-forming units (PFUs) per milliliter for Pseudomon

223 days before challenge with either 1 x 10(7) plaque-forming units (PFUs) VSV-SUDV, VSV-EBOV, or contr

224 d hospitalized patients (log(10) 3.7 +/- 1.7 plaque-forming units (PFUs)/mL vs 2.4 +/- 1.1 PFUs/mL, P

225 various vector doses [1 x 10(6) to 2 x 10(9) plaque-forming units (PFUs)] prior to imaging.

226 6-24 months received 1 intranasal dose (105 plaque-forming units [PFUs] of D46/NS2/N/DeltaM2-2-HindI

227 a single injection of AdRSVpHyde (5 x 10(9) plaque-forming units) reduced DU145 tumors in nude mice

228 njection of tumors with Ad.mIL-12 (1 x 10(9) plaque-forming units) results in a complete tumor regres

229 gle intratumoral administration of 2 x 10(9) plaque-forming unit(s) of Ad-OC-E1a.

230 Rats transduced with 1x10(9) plaque-forming units show decremental cardiac luciferase

231 1, with subsequent monthly boosts of 1x10(9) plaque-forming units, starting on day 15.

232 In rats dosed with this agent (2.2 x 10(9) plaque-forming units), the time course of expression was

233 ) were injected with AdSDF-1alpha (5 x 10(8) plaque-forming units), there was an accumulation of dend

234 hosphamide-suppressed animals, the ratios of plaque-forming units to LD50 decreased by at least four

235 nfection, but it did not alter the ratios of plaque-forming units to LD50 or affect the HSV-induced i

236 s evidenced by decreased viral titers (10(5) plaque-forming units to undetectable), and restoration o

237 ns of Ad-FHIT, at a total dose of 3 x 10(10) plaque-forming units/tumor for H1299 tumors and 4 x 10(1

238 1) (P<0.05 for 1x10(9), 1x10(8), and 1x10(7) plaque-forming units versus control adenovirus-expressin

239 ro with adenovirus murine FVIII (3.3 x 10(5) plaque-forming units) was 87%.

240 l-channel PSPWB for S-OIV is 30 PFU/mL (PFU, plaque-forming unit), which was calculated from the fitt

241 say, 50 microm BIP caused a 50% reduction in plaque-forming units with either virus.

242 lication-incompetent adenovirus (0-2 x 10(9) plaque-forming units) with the E1 region deleted (n = 8)

243 tions were found to contain more genomes per plaque-forming unit, with larger diameters.